Skip to main content
. 2017 Dec 16;17:252. doi: 10.1186/s12886-017-0648-3

Table 2.

Primary and secondary endpoints and safety endpoints

Patient 1 Patient 2 Patient 3
Primary endpoint (month 2)
 VH (reduction) score 0.5+ 0.5+ (−1) 0 (−1.5)
Secondary endpoint (month 6)
 BCVA in ETDRS-letters (gain) 82 (+17) 79 (+24) 69 (+11)
 CRT in μm (reduction) 265 (−186) 319 (−1) 267 (−83)
 Concomitant medication (change) CSA 2.1 mg/kg bodyweight daily, (+Decortin 0.1 mg/kg bodyweight once daily) Decortin 0.2 mg/kg bodyweight once daily MTX 6.25 mg/m2/once weekly (−MTX 2.5 mg weekly; − Decortin 0.03 mg/kg bodyweight once daily)
Safety endpoints (month 6)
 IOP 19 11 13
 Number of IOP lowering medications during study course (topical or oral) 3 (topical) 2 (topical) 5 (4 topical, 1 oral)
 Number of IOP lowering surgeries during study course 0 0 0
 CDR (increase) 0.2 0.2 0.2 (+0.1)
 Cataract status clear clear Subcapsular cataract grade 2+ (no progression)

VH vitreous haze, BCVA best corrected visual acuity, ETDRS- letters Early Treatment of Diabetic Retinopathy- letters, CRT central retinal thickness, IOP intraocular pressure, CDR cup/ disc- ratio optic nerve head